GlaxoSmithKline Pharmaceuticals Ltd (GSK India), a subsidiary of GlaxoSmithKline Plc, develops and markets vaccines and medicines. The company focuses on four therapeutic areas: infectious diseases, HIV, oncology, and immunology. The company’s product portfolio comprises a broad range of general medicines which include vitamins minerals nutritionals, hormones, dermatologicals, anti-infectives, pain management, respiratory and vaccines for children and adults.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

GSK India is at the forefront of addressing critical healthcare challenges through innovative research and development across multiple therapeutic areas. GSK India is dedicated to combating antimicrobial resistance (AMR) by participating in local and national forums and emphasizing responsible antibiotic use. The company leads educational initiatives, including the Advanced Surgical Conclave for ENTs (ASCENT), and engages in research to provide real-world data on antibiotic susceptibility. Over 250 medical-led scientific presentations have reached approximately 25,000 healthcare professionals (HCPs), enhancing their ability to select appropriate antibiotics. GSK India promotes effective management of skin disorders through flagship programs such as Bridging Insights from Dermatology Group of Experts (BRIDGE) and Dermalogue. It has organized over 351 case study clinics and engaged more than 3,000 institutional dermatologists in scientific discussions, collaborating with six national and international experts. Addressing the high prevalence of hypothyroidism among Indian women, GSK India hosted five Cross Specialty Experts Symposium (CREST 2.0) meetings. These sessions, led by 18 experts, trained approximately 900 HCPs on optimal hypothyroidism management. GSK India supports pediatric vaccination through regional obstetric societies and MyVaccinationHub.in campaigns. The company has facilitated 533 one-on-one interactions with HCPs, delivered new data on Neonatal Pertussis and Hepatitis A, and published papers advocating for pediatric vaccines. GSK India has introduced Shingrix and received Phase III trial approval for Herpes Zoster, and regulatory extension for Fluarix Tetra for individuals aged 65 and above. The company is also advancing scientific advocacy for Shingles prevention. GSK India is engaged in significant specialty research, including the PRISM Phase IV study for severe asthma, recruitment for Trelegy in COPD, and multi-country studies on Mepolizumab. The company has conducted four Eosinoverse education programs, supported 14,500 asthma diagnoses through INSIPRA clinics, and facilitated home administration of Mepolizumab for 223 patients. It has also obtained regulatory approvals for Zejula and Jemperli for gynecological cancers. The company spent INR25.4 million on research and development in FY2024, which as a percentage of revenue stood at 0.07%.